Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Inventory (2016 - 2025)

Historic Inventory for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $146.5 million.

  • Ani Pharmaceuticals' Inventory fell 105.85% to $146.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.5 million, marking a year-over-year decrease of 105.85%. This contributed to the annual value of $136.8 million for FY2024, which is 2300.98% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Inventory stood at $146.5 million for Q3 2025, which was down 105.85% from $138.3 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Inventory high stood at $148.0 million for Q3 2024, and its period low was $65.4 million during Q1 2021.
  • For the 5-year period, Ani Pharmaceuticals' Inventory averaged around $108.9 million, with its median value being $105.4 million (2022).
  • In the last 5 years, Ani Pharmaceuticals' Inventory surged by 5743.95% in 2022 and then crashed by 105.85% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Inventory stood at $89.4 million in 2021, then rose by 17.79% to $105.4 million in 2022, then increased by 5.54% to $111.2 million in 2023, then increased by 23.01% to $136.8 million in 2024, then increased by 7.09% to $146.5 million in 2025.
  • Its Inventory stands at $146.5 million for Q3 2025, versus $138.3 million for Q2 2025 and $137.4 million for Q1 2025.